BRVE Braveheart Bio, Inc.
Nasdaq · SEC CIK 2131524 · EDGAR
- Bought, last 12 months
- $159.03M 11 purchases by 10 insiders
- Sold, last 12 months
- $0 0 sales by 0 insiders
- Filings on record
- 14 since 2026-08-07, latest 2026-08-11 17:53
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Forbion Growth Opportunities Fund III Cooperatief U.A. | 10% | $64.80M | — |
| Chimovits Erez | Dir, 10% | $34.92M | — |
| ORBIMED ADVISORS LLC | Dir, 10% | $34.92M | — |
| AH Bio Fund IV, L.P. | 10% | $19.80M | — |
| Murdoch Travis | CEO, Pres, Dir | $1.50M | — |
| Viehbacher Christopher | Dir | $1.50M | — |
| Lubner David Charles | Dir | $1000.0K | — |
| Rickey James Paul | CFO | $500.0K | — |
| Malek David I | Dir | $75.0K | — |
| Anderson Michele A. | Chief Development Off | $20.0K | — |
Transactions 17
Purchase Sale Sale after option exercise All abbreviations
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2026-08-11 17:53 | 2026-08-07 | BRVE | AH Bio Fund IV, L.P. | 10% | C - Cnv Deriv | — | +9.13M | 9.13M | New | — |
| DI | 2026-08-11 17:53 | 2026-08-07 | BRVE | AH Bio Fund IV, L.P. | 10% | P - Purchase | $18.00 | +1.10M | 10.23M | +12% | +$19.80M |
| DI | 2026-08-11 17:31 | 2026-08-07 | BRVE | Chimovits Erez | Dir, 10% | C - Cnv Deriv | — | +9.13M | 10.24M | +828% | — |
| DMI | 2026-08-11 17:31 | 2026-08-07 | BRVE | Chimovits Erez | Dir, 10% | P - Purchase | $18.00 | +1.94M | 273.3K | New | +$34.92M |
| DI | 2026-08-11 17:27 | 2026-08-07 | BRVE | ORBIMED ADVISORS LLC | Dir, 10% | C - Cnv Deriv | — | +9.13M | 10.24M | +828% | — |
| DMI | 2026-08-11 17:27 | 2026-08-07 | BRVE | ORBIMED ADVISORS LLC | Dir, 10% | P - Purchase | $18.00 | +1.94M | 273.3K | New | +$34.92M |
| D | 2026-08-10 10:03 | 2026-08-07 | BRVE | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 10% | C - Cnv Deriv | — | +7.42M | 7.42M | New | — |
| D | 2026-08-07 17:25 | 2026-08-07 | BRVE | Forbion Growth Opportunities Fund III Cooperatief U.A. | 10% | C - Cnv Deriv | $0.00 | +9.13M | 9.72M | +1,553% | $0 |
| DI | 2026-08-07 17:25 | 2026-08-07 | BRVE | Forbion Growth Opportunities Fund III Cooperatief U.A. | 10% | C - Cnv Deriv | $0.00 | +7.99M | 8.51M | +1,553% | $0 |
| D | 2026-08-07 17:25 | 2026-08-07 | BRVE | Forbion Growth Opportunities Fund III Cooperatief U.A. | 10% | P - Purchase | $18.00 | +1.92M | 11.64M | +20% | +$34.56M |
| DI | 2026-08-07 17:25 | 2026-08-07 | BRVE | Forbion Growth Opportunities Fund III Cooperatief U.A. | 10% | P - Purchase | $18.00 | +1.68M | 10.19M | +20% | +$30.24M |
| D | 2026-08-07 16:41 | 2026-08-07 | BRVE | Rickey James Paul | CFO | P - Purchase | $18.00 | +27.8K | 520.9K | +6% | +$500.0K |
| D | 2026-08-07 16:31 | 2026-08-07 | BRVE | Viehbacher Christopher | Dir | P - Purchase | $18.00 | +83.3K | 609.5K | +16% | +$1.50M |
| D | 2026-08-07 16:31 | 2026-08-07 | BRVE | Malek David I | Dir | P - Purchase | $18.00 | +4,166 | 533.8K | +0.8% | +$75.0K |
| D | 2026-08-07 16:30 | 2026-08-07 | BRVE | Anderson Michele A. | Chief Development Off | P - Purchase | $18.00 | +1,111 | 332.2K | +0.3% | +$20.0K |
| D | 2026-08-07 16:30 | 2026-08-07 | BRVE | Murdoch Travis | CEO, Pres, Dir | P - Purchase | $18.00 | +83.3K | 2.94M | +3% | +$1.50M |
| D | 2026-08-07 16:30 | 2026-08-07 | BRVE | Lubner David Charles | Dir | P - Purchase | $18.00 | +55.6K | 55.6K | New | +$1000.0K |